The following is a summary of “Should we use nomograms for risk predictions in diffuse large B cell lymphoma patients? A systematic review,” published in the February 2024 issue of Oncology by Jelicic et al.
Nomograms have garnered significant interest as prognostic tools for patients with Diffuse Large B Cell Lymphoma (DLBCL), offering potential insights into disease outcomes. In this systematic review, the researchers examined 59 articles from January 2000 to 2024 that proposed prognostic models for DLBCL, incorporating various parameters such as clinical, laboratory, immunohistochemical, and genetic factors. Among these studies, 40 focused on gene expression signatures and integrated them into nomogram-based prognostic models.
While many of these models assessed discrimination and calibration during development, a notable proportion lacked external validation. Presently, nomogram-based models for DLBCL are primarily derived from publicly available databases, presenting a gap in external validation and applicability in clinical practice. Nonetheless, these nomograms may hold utility in individual patient counseling, provided careful consideration is given to their development and potential limitations when employed for prognostication.
Source: sciencedirect.com/science/article/pii/S1040842824000362
